EZZ Life Science Holdings Limited (ASX:EZZ – Get Free Report) insider Mark (Qizhou) Qin bought 90,830 shares of the stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average price of A$2.71 ($1.73) per share, for a total transaction of A$246,149.30 ($156,782.99).
EZZ Life Science Price Performance
The company has a current ratio of 5.96, a quick ratio of 4.53 and a debt-to-equity ratio of 0.58.
EZZ Life Science Increases Dividend
The business also recently declared a Final dividend, which was paid on Sunday, December 8th. Investors of record on Sunday, December 8th were issued a $0.02 dividend. This represents a dividend yield of 0.57%. The ex-dividend date of this dividend was Monday, November 4th. This is a boost from EZZ Life Science’s previous Final dividend of $0.01. EZZ Life Science’s payout ratio is 37.50%.
About EZZ Life Science
EZZ Life Science Holdings Limited engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally. The company operates in two segments, Brought in Lines and Company Owned Products. It is also involved in the wholesale distribution of the EAORON branded skin care products to retailers; and research and development, and sale of genomics and precision nutrition research products under the EZZ brand.
See Also
- Five stocks we like better than EZZ Life Science
- Quiet Period Expirations Explained
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- How to Effectively Use the MarketBeat Ratings Screener
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- CD Calculator: Certificate of Deposit Calculator
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for EZZ Life Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EZZ Life Science and related companies with MarketBeat.com's FREE daily email newsletter.
